問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Rheumatology

Division of General Internal Medicine

Taipei Veterans General Hospital

Division of Rheumatology

更新時間：2023-09-19

曾瑞成
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾瑞成

List

57Cases

2021-05-28 - 2023-06-09

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2022-08-01 - 2024-09-13

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Not yet recruiting2Sites

2020-08-27 - 2023-12-18

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis

  • Condition/Disease

    Active Lupus Nephritis

  • Test Drug

    Guselkumab

Participate Sites
4Sites

Recruiting4Sites

2012-12-01 - 2015-12-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy

  • Condition/Disease

    Active Rheumatoid Arthritis

  • Test Drug

    CNTO136

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2012-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-08-11 - 2020-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    CNTO1959(guselkumab)

Participate Sites
7Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

2014-05-01 - 2020-12-31

Phase III

A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    CNTO136 (sirukumab)

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

藍忠亮
China Medical University Hospital

2015-09-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic Axial Spondyloarthritis

  • Condition/Disease

    Active Radiographic Axial Spondyloarthritis

  • Test Drug

    STELARA

Participate Sites
10Sites

Terminated10Sites

2015-09-01 - 2020-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2015-09-01 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

羅淑芬
Linkou Chang Gung Medical Foundation

Division of Rheumatology

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB